No Longer Available EXPANDED_ACCESS NCT06841874
Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC (Tale EAP)
Sponsor: Nuvation Bio Inc.
Conditions
Bronchogenic Carcinoma Carcinoma Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Non Small Cell Carcinoma of the Lung ROS1-positive Non-Small Cell Lung Cancer (NSCLC) Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms
Interventions
Taletrectinib
Updated 2 times since 2025 Last updated: Dec 17, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06841874, this observational or N/A phase trial focuses on Bronchogenic Carcinoma and Carcinoma and remains ongoing. Sponsored by Nuvation Bio Inc., it has been updated 2 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
2 versions recorded-
Jan 2026 — Present [monthly]
No Longer Available
Status: Available → No Longer Available
-
Mar 2025 — Jan 2026 [monthly]
Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Nuvation Bio Inc.
Data source: Nuvation Bio Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.